Pharmacological Management of Psychosis in Elderly Patients with Parkinsonism

American Journal of Medicine

Volumn 122, Issue 7, 2009, Pages 614-622

  Hasnain, Mehrul ^a   Vieweg, W Victor R ^b,c   Baron, Mark S ^b,c   Beatty Brooks, Mary ^b   Fernandez, Antony ^b,c   Pandurangi, Anand K ^c  

^a Sir Thomas Roddick Hospital Stephenville   (Canada)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Antipsychotic drugs; Basal ganglia; Dementia; Lewy bodies; Parkinson's disease; Psychosis

Indexed keywords

ANTIPARKINSON AGENT; APOMORPHINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE MESILATE; CARBIDOPA PLUS LEVODOPA; CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; ENTACAPONE; GALANTAMINE; HALOPERIDOL; MEMANTINE; NEMANDA; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERGOLIDE; PERIMAX; PRAMIPEXOLE; QUETIAPINE; RASAGILINE; RISPERIDONE; RIVASTIGMINE; ROTIGOTINE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG; ZELEPAR; ZIPRASIDONE;

AGING; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CARDIOMYOPATHY; CLINICAL TRIAL; COMORBIDITY; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DIZZINESS; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DROWSINESS; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; GERIATRIC CARE; HUMAN; HYPERGLYCEMIA; LOW DRUG DOSE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MYOCARDITIS; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; TREMOR; WEIGHT GAIN;

EID: 67649743694     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.01.025     Document Type: Note

References (89)

1. Bennett D.A., Beckett L.A., Murray A.M., et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 334 (1996) 71-76
2. Friedman J.H., Skeete R., and Fernandez H.H. Unrecognized parkinsonism in acute care medical patients receiving neurological consultations. J Gerontol A Biol Sci Med Sci 58 (2003) 94-95
3. Friedman J.H., Fernandez H.H., and Trieschmann M.M. Parkinsonism in a nursing home: underrecognition. J Geriatr Psychiatry Neurol 17 (2004) 39-41
4. Weintraub D., and Hurtig H.I. Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies. Am J Psychiatry 164 (2007) 1491-1498
5. McKeith I.G., Dickson D.W., Lowe J., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65 (2005) 1863-1872
6. Savitt J.M., Dawson V.L., and Dawson T.M. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 116 (2006) 1744-1754
7. de Rijk M.C., Breteler M.M., Graveland G.A., et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 45 (1995) 2143-2146
8. Morens D.M., Davis J.W., Grandinetti A., et al. Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men. Neurology 46 (1996) 1044-1050
9. Aarsland D., Bronnick K., Ehrt U., et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 78 (2007) 36-42
10. Factor S.A., Feustel P.J., Friedman J.H., et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 60 (2003) 1756-1761
11. Aarsland D., Andersen K., Larsen J.P., et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60 (2003) 387-392
12. Zaccai J., McCracken C., and Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 34 (2005) 561-566
13. Kosaka K. Diffuse Lewy body disease in Japan. J Neurol 237 (1990) 197-204
14. Nussbaum R.L., and Ellis C.E. Alzheimer's disease and Parkinson's disease. N Engl J Med 348 (2003) 1356-1364
15. Mitchell S.L. Extrapyramidal features in Alzheimer's disease. Age Ageing 28 (1999) 401-409
16. Ropacki S.A., and Jeste D.V. Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry 162 (2005) 2022-2030
17. Stern Y., Albert M., Brandt J., et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analyses from the Predictors Study. Neurology 44 (1994) 2300-2307
18. Damier P., Hirsch E.C., Agid Y., and Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122 Pt 8 (1999) 1437-1448
19. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., et al. The basal ganglia and disorders of movement: pathophysiological mechanisms. News Physiol Sci 17 (2002) 51-55
20. Kuzuhara S., and Yoshimura M. Clinical and neuropathological aspects of diffuse Lewy body disease in the elderly. Adv Neurol 60 (1993) 464-469
21. Camicioli R., Kaye J., Payami H., et al. Apolipoprotein E epsilon4 is associated with neuronal loss in the substantia nigra in Alzheimer's disease. Dement Geriatr Cogn Disord 10 (1999) 437-441
22. Brown F.W. The neurobiology of late-life psychosis. Crit Rev Neurobiol 7 (1993) 275-289
23. Keshavan M.S., Berger G., Zipursky R.B., et al. Neurobiology of early psychosis. Br J Psychiatry Suppl 48 (2005) s8-s18
24. Miyamoto S., LaMantia A.S., Duncan G.E., et al. Recent advances in the neurobiology of schizophrenia. Mol Interv 3 (2003) 27-39
25. Meeks T.W., Ropacki S.A., and Jeste D.V. The neurobiology of neuropsychiatric syndromes in dementia. Curr Opin Psychiatry 19 (2006) 581-586
26. Perry E.K., Marshall E., Kerwin J., et al. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem 55 (1990) 1454-1456
27. Rochon P.A., Stukel T.A., Sykora K., et al. Atypical antipsychotics and parkinsonism. Arch Intern Med 165 (2005) 1882-1888
28. Hughes A.J., Daniel S.E., Kilford L., and Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55 (1992) 181-184
29. Rajput A.H., Rozdilsky B., and Rajput A. Accuracy of clinical diagnosis in parkinsonism-a prospective study. Can J Neurol Sci 18 (1991) 275-278
30. Wijkstra J., Lijmer J., Balk F., et al. Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev (2005) CD004044
31. Young J., and Inouye S.K. Delirium in older people. BMJ 334 (2007) 842-846
32. Turjanski N., and Lloyd G.G. Psychiatric side-effects of medications: recent developments. Adv Psychiatr Treatment 11 (2005) 58-70
33. Kuzuhara S. Drug-induced psychotic symptoms in Parkinson's disease. Problems, management and dilemma. J Neurol 248 Suppl 3 (2001) III28-III31
34. Ellis T., Cudkowicz M.E., Sexton P.M., and Growdon J.H. Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 12 (2000) 364-369
35. Frieling H., Hillemacher T., Ziegenbein M., et al. Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis. Eur Neuropsychopharmacol 17 (2007) 165-171
36. Goetz C.G., Blasucci L.M., Leurgans S., and Pappert E.J. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 55 (2000) 789-794
37. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 340 (1999) 757-763
38. Pollak P., Tison F., Rascol O., et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 75 (2004) 689-695
39. Fernandez H.H., Donnelly E.M., and Friedman J.H. Long-term outcome of clozapine use for psychosis in parkinsonian patients. Mov Disord 19 (2004) 831-833
40. Klein C., Gordon J., Pollak L., and Rabey J.M. Clozapine in Parkinson's disease psychosis: 5-year follow-up review. Clin Neuropharmacol 26 (2003) 8-11
41. Burke W.J., Pfeiffer R.F., and McComb R.D. Neuroleptic sensitivity to clozapine in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 10 (1998) 227-229
42. Fernandez H.H., Trieschmann M.E., and Friedman J.H. Treatment of psychosis in Parkinson's disease: safety considerations. Drug Saf 26 (2003) 643-659
43. Rich S.S., Friedman J.H., and Ott B.R. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 56 (1995) 556-559
44. Leopold N.A. Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov Disord 15 (2000) 301-304
45. Ondo W.G., Levy J.K., Vuong K.D., et al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 17 (2002) 1031-1035
46. Miyasaki J.M., Shannon K., Voon V., et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66 (2006) 996-1002
47. Walker Z., Grace J., Overshot R., et al. Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry 14 (1999) 459-466
48. Cummings J.L., Street J., Masterman D., and Clark W.S. Efficacy of olanzapine in the treatment of psychosis in dementia with Lewy bodies. Dement Geriatr Cogn Disord 13 (2002) 67-73
49. Friedman J.H., and Factor S.A. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 15 (2000) 201-211
50. Friedman J.H., and Fernandez H.H. Atypical antipsychotics in Parkinson-sensitive populations. J Geriatr Psychiatry Neurol 15 (2002) 156-170
51. Merims D., Balas M., Peretz C., et al. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 29 (2006) 331-337
52. Ondo W.G., Tintner R., Voung K.D., et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 20 (2005) 958-963
53. Prohorov T., Klein C., Miniovitz A., et al. The effect of quetiapine in psychotic parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. J Neurol 253 (2006) 171-175
54. Rabey J.M., Prokhorov T., Miniovitz A., et al. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord 22 (2007) 313-318
55. Fernandez H.H., Trieschmann M.E., Burke M.A., et al. Long-term outcome of quetiapine use for psychosis among parkinsonian patients. Mov Disord 18 (2003) 510-514
56. Klein C., Prokhorov T., Miniovich A., et al. Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis. Clin Neuropharmacol 29 (2006) 215-219
57. Fernandez H.H., Trieschmann M.E., Burke M.A., and Friedman J.H. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry 63 (2002) 513-515
58. Takahashi H., Yoshida K., Sugita T., et al. Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 549-553
59. Fernandez H.H., Trieschmann M.E., and Friedman J.H. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 27 (2004) 4-5
60. Friedman J.H., Berman R.M., Goetz C.G., et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 21 (2006) 2078-2081
61. Lopez-Meza E., Ruiz-Chow A., and Ramirez-Bermudez J. Aripiprazole in psychosis associated with Parkinson's disease. J Neuropsychiatry Clin Neurosci 17 (2005) 421-422
62. Mega M.S., Cummings J.L., Fiorello T., and Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 46 (1996) 130-135
63. Beier M.T. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention. Pharmacotherapy 27 (2007) 399-411
64. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry 9 (2001) 361-381
65. Grimmer T., and Kurz A. Effects of cholinesterase inhibitors on behavioural disturbances in Alzheimer's disease: a systematic review. Drugs Aging 23 (2006) 957-967
66. Liepelt I., Maetzler W., Blaicher H.P., et al. Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors. Dement Geriatr Cogn Disord 23 (2007) 351-367
67. Ballard C., and Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev (2006) CD003476
68. Daiello L.A. Atypical antipsychotics for the treatment of dementia-related behaviors: an update. Med Health R I 90 (2007) 191-194
69. Sink K.M., Holden K.F., and Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 293 (2005) 596-608
70. Deberdt W.G., Dysken M.W., Rappaport S.A., et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry 13 (2005) 722-730
71. Schneider L.S., Tariot P.N., Dagerman K.S., et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 355 (2006) 1525-1538
72. Tariot P.N., Schneider L., Katz I.R., et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry 14 (2006) 767-776
73. Mintzer J.E., Tune L.E., Breder C.D., et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry 15 (2007) 918-931
74. Haas S.J., Hill R., Krum H., et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 30 (2007) 47-57
75. Vieweg W.V. New generation antipsychotic drugs and QTc interval prolongation. Prim Care Companion J Clin Psychiatry 5 (2003) 205-215
76. Hasnain M., Vieweg W.V.R., Fredrickson S.K., et al. Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. Prim Care Diabetes 3 (2009) 5-15 Epub 2008 Dec 10
77. Bullock R. Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings. Curr Med Res Opin 21 (2005) 1-10
78. FDA Public Health Advisory. Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. April 11, 2005. http://www.fda.gov/Cder/drug/advisory/antipsychotics.htm Accessed September 24, 2008
79. Bhasin M., Rowan E., Edwards K., and McKeith I. Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis. Int J Geriatr Psychiatry 22 (2007) 890-895
80. Edwards K., Royall D., Hershey L., et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dement Geriatr Cogn Disord 23 (2007) 401-405
81. Rozzini L., Chilovi B.V., Bertoletti E., et al. Cognitive and psychopathologic response to rivastigmine in dementia with Lewy bodies compared to Alzheimer's disease: a case control study. Am J Alzheimers Dis Other Demen 22 (2007) 42-47
82. Thomas A.J., Burn D.J., Rowan E.N., et al. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 20 (2005) 938-944
83. FDA Approves the First Treatment for Dementia of Parkinson's Disease. June 27, 2006. http://www.fda.gov/bbs/topics/NEWS/2006/NEW01399.html Accessed September 24, 2008
84. Miller L.J. The use of cognitive enhancers in behavioral disturbances of Alzheimer's disease. Consult Pharm 22 (2007) 754-762
85. Wynn Z.J., and Cummings J.L. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dement Geriatr Cogn Disord 17 (2004) 100-108
86. Mori S., Mori E., Iseki E., and Kosaka K. Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study. Psychiatry Clin Neurosci 60 (2006) 190-195
87. Sobow T. Parkinson's disease-related visual hallucinations unresponsive to atypical antipsychotics treated with cholinesterase inhibitors: a case series. Neurol Neurochir Pol 41 (2007) 276-279
88. Aarsland D., Hutchinson M., and Larsen J.P. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 18 (2003) 937-941
89. Shea C., MacKnight C., and Rockwood K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 10 (1998) 229-238